Ali Faraz 4

What Happened
Ali Faraz, CEO of Tenaya Therapeutics, sold a total of 14,862 shares in open-market transactions on February 17, 2026. The shares were sold at prices ranging from $0.6075 to $0.671 (weighted average $0.64), generating total proceeds of $9,557. These sales were made to satisfy tax withholding obligations tied to vested restricted stock units (RSUs), not as independent discretionary stock sales.

Key Details

• Transaction date: 2026-02-17 (filed same day).
• Sales: 5,851 shares for $3,762; 3,979 shares for $2,559; 5,032 shares for $3,236 — total 14,862 shares for $9,557.
• Price range: $0.6075 – $0.671; weighted average price reported $0.64 (footnote notes detailed per-price breakdown available on request).
• Reason: Shares sold to cover tax withholding on RSU vestings (footnotes reference RSU awards from Feb 15, 2023; Feb 23, 2024; Feb 6, 2025).
• Ownership note: The filing discloses unvested RSUs that will convert to common stock — footnotes list 354,250; 343,625; and 330,187 shares tied to different award grants (totaling 1,028,062 RSU shares) that are included in beneficial ownership disclosure. The Form 4 does not separately list a simple “shares owned after transaction” total for fully vested shares in the items you provided.
• Timeliness: Report appears to have been filed on the transaction date (not late).

Context
Sales labeled as tax-withholding (cashless) for RSU vesting are routine and common for executives; they do not necessarily indicate a change in the insider’s view of the company. This transaction code is F (tax withholding) / S (sale) rather than a discretionary open-market sell for investment reasons.